Public Education Forum
THE ANNUAL ALZHEIMER’S PUBLIC EDUCATIONAL FORUM
Sunday, March 6, 2022 (1:30 pm – 3:30 pm US Eastern Time)
The event was free-for-all and was held online via Zoom.
Schedule
2022 Alzheimer’s Disease Public Educational Forum
CHAIRS:
Ranjan Duara, MD, FAAN, Mount Sinai Medical Center
Rosie Curiel Cid, PsyD, University of Miami Miller School of Medicine
This event was intended for the public at large, including individuals at-risk for AD, their family members, as well as professionals from various fields who may be interested in an up-to-date review of some aspects of AD research.
Sunday, March 6, 2022
All times in US Eastern Time.
THE EVENT WAS followed BY THE CE-ACCREDITED CARE PARTNER EDUCATIONAL FORUM FROM 3:45PM et THROUGH 5:45pm et.
1:30 pm
1:35
1:35
Topic introduction (effect of the pandemic on patients, managing neuropsychiatric challenges, life after COVID)
1:40
Questions and Discussion
1:55
1:55
Topic introduction
2:00
Questions and Discussion
2:15
2:15
Topic introduction (difference between MCI and AD, predicting rate of progression; neuropsychiatric feaures)
2:20
Questions and Discussion
2:35
2:35
Topic introduction
2:40
Questions and Discussion
2:55
2:55
Topic introduction
3:00
Questions and Discussion
3:15
3:30
Ranjan Duara, MD, FAAN, Mount Sinai Medical Center
Rosie Curiel Cid, PsyD, University of Miami Miller School of Medicine
Registration was free and open to all.
Miami-Dade Area Health Education Center (AHEC), Inc. is an approved continuing education credit provider (CE Broker Provider # 50-1349) through the Florida Board of Nursing (RN, APRN, LPN) and Florida Board of Clinical Social Work, Marriage and Family Therapy and Mental Health Counseling (LCSW, LMFT, LMHC) and the Florida Board of Psychology (PY).
This event has been approved for a maximum of 2.0 CEUs for RN, APRN & LPN, 2.0 CEUs for LCSW, LMFT and LMHC & 2.0 CEUs for PY.
Credit earnings are commensurate with course participation. Participants will only earn CEUs for a successfully completed course.
CE Broker Course Tracking# 20-902789
PANELISTS
Dr. Marc Agronin is Senior Vice President at the Behavioral Health and Chief Medical Officer for MIND Institute and leads Miami Jewish Health’s MIND Institute. He is the driving force in the development of Miami Jewish Health’s EmpathiCare℠ philosophy and the future EmpathiCare℠ Village.
Dr. Marc Agronin has been part of Miami Jewish Health since 1999. He is a leading expert in Alzheimer’s disease and geriatric mental health issues, and a nationally-sought author and speaker. Agronin has written 10 books, including the critically acclaimed The End of Old Age: Living a Longer, More Purposeful Life (2018), How We Age: A Doctor’s Journey into the Heart of Growing Old (2011), and The Dementia Caregiver: A Guide to Caring for Someone with Alzheimer’s Disease and Other Neurocognitive Disorders (2016). Dr. Agronin has published articles in The New York Times and Scientific American Mind and is a regular contributor on aging and retirement issues to The Wall Street Journal.
Dr. Agronin holds a Bachelor of Arts in psychology and philosophy from Harvard University and obtained his Doctor of Medicine degree from the Yale School of Medicine. He completed his residency training in psychiatry at Harvard Medical School and fellowship in geriatric psychiatry at the VA Medical Center in Minneapolis, Minnesota.
Dr. Agronin oversees all behavioral health services at Miami Jewish Health, and personally sees all patients and subjects at MIND Institute, whether being evaluated for cognitive changes or participating in a clinical trial. He believes in practicing medicine the way he saw his grandfather tend to patients for over 50 years in a small Midwestern town, with total dedication and personal, empathic attention.
Agronin was named the 2008 Clinician of the Year by the American Association for Geriatric Psychiatry, is a Distinguished Fellow of the American Psychiatric Association and the American Association for Geriatric Psychiatry, and was the recipient of the Excellence in Research and Education Award by LeadingAge. He is also an Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine.
Additional resources: miamijewishhealth.org/leadership/marc-e-agronin/
Dr. Howard Chertkow is a cognitive neurologist and co-founder and Director of the Jewish General Hospital / McGill Memory Clinic, the largest such clinic in Canada. He has been continuously funded by the Canadian Institutes for Health Research (CIHR) and its forerunner, the MRC, for the past 20 years. He currently holds CIHR grants to explore the natural history of mild cognitive impairment and the neural substrate of semantic memory.
Dr. Chertkow is past President of the Canadian Consortium of Centres for Clinical Cognitive Research (C5R). He was coordinator of the cognition axis of the FRSQ Network on Aging. He currently sits on the Research Advisory Board of the Alzheimer Society of Canada, and was a key member of a Quebec committee mandated in 2008 to draw up a provincial strategy for dementia management. He is the only non-American sitting on the NIH committee which funds Alzheimer’s Disease Research Centres across the United States. Dr. Chertkow is the Scientific Organizer of the 2011 world meeting of Alzheimer’s Disease International.
Dr. Chertkow’s major areas of research include: 1) early diagnosis of Alzheimer’s Disease and prediction of deterioration in individuals with mild cognitive impairment; 2) the structure, organization, and function of the semantic memory component of long term memory and its deterioration in dementia; 3) localization of language and memory functions in the brain using functional imaging; and 4) development of knowledge transfer tools to allow physicians to better diagnose cognitive decline.
He was among the first researchers to recognize and describe the loss of long term semantic memory that occurs in Alzheimer’s Disease, along with describing abnormalities of increased semantic priming in that condition. His laboratory has carried out ground-breaking work in mild cognitive impairment and was the first to describe imaging changes, such as abnormal magnetization transfer ratios.
In 2005, he and his colleagues, Ziad Nasreddine and Natalie Phillips, published the Montreal Cognitive Assessment (MoCA), now used around the world to screen for cognitive loss in the elderly. Thompson Reuters’ Essential Science Indicators noted this to be the most cited paper in mild cognitive impairment, 2006-2009.
Dr. Rosie Curiel Cid is a Neuropsychologist and Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine and Chief of Cross-Cultural Neuropsychology and Cognitive Neuroscience at the Center for Cognitive Neuroscience and Aging. Dr. Curiel Cid specializes in the early cognitive and functional assessment of neurodegenerative conditions, such as Alzheimer’s disease and related disorders.
She is Principal Investigator of a longitudinal study funded by the National Institutes of Health/National Institute on Aging entitled: Precision-based Computerized Assessment for the Detection of MCI in Older Adults, and is an active Co-investigator on various state and federally funded studies related to aging and cognition including the 1Florida Alzheimer’s Disease Research Center.
Her program of research focuses on the development of novel and cross-culturally applicable cognitive assessment paradigms. She along with Dr. David Loewenstein and their team have generated promising data that these novel cognitive outcome measures are sensitive enough to detect subtle cognitive deficits specific to preclinical Alzheimer’s disease, and are highly associated with biological markers of early AD brain pathology including CSF markers, amyloid imaging and structural and functional neuroimaging. Dr. Curiel Cid’s work focuses on technologically enhancing these innovative cognitive paradigms into user-friendly clinical outcome measures with the goal of advancing cognitive assessment efforts in clinical trials targeting preclinical disease. She and her team have led the development of the brief computerized version of the renowned LASSI-L, a cognitive stress test that has shown sensitivity and specificity at detecting cognitive change in preclinical and prodromal Alzheimer’s disease.
Dr. Steven DeKosky, a prominent Alzheimer’s disease and traumatic brain injury researcher and UF alumnus, came to UF in July 2015 as the institute’s deputy director and professor of neurology in the College of Medicine.
Prior to joining the McKnight Brain Institute, Dr. DeKosky was vice president and dean of the University of Virginia School of Medicine from 2008 to 2013, and was then appointed emeritus professor of neurology. Prior to becoming dean at UVA, he spent 18 years at the University of Pittsburgh in roles that included chair of the department of neurology and director of the Alzheimer’s Disease Research Center.
As a researcher, Dr. DeKosky focused on understanding the neurochemistry, neuroimaging, treatment and prevention of Alzheimer’s disease in both his laboratory and in clinical research. He also co-authored the first report of the dementia associated with traumatic brain injuries among professional football players and published extensively in basic research of TBI.
At UF, Dr. DeKosky did graduate work in psychology and neuroscience, received a medical degree in 1974 and following an internship at The Johns Hopkins Hospital, returned to UF to complete a residency in neurology, followed by a fellowship in neurochemistry at the University of Virginia Center for Neurosciences.
Additional resources: neurology.ufl.edu/profile/dekosky-steven/
Dr. Duara’s research has focused primarily on early diagnosis of Alzheimer’s disease and other dementias, neuroimaging, genetic epidemiology and the methodology for staging the transition from normal cognitive aging to dementia. He has contributed to over 200 articles in peer-review scientific journals as well many book chapters.
He is the Principal Investigator for the State of Florida Alzheimer’s Disease Initiative Brain Bank and Associate Director of the 1FLORIDA Alzheimer’s Disease Research Center. He has also been an investigator in numerous clinical trials of novel agents for the treatment of Alzheimer’s Disease.
Additional resources: msmc.com/doctor/ranjan-duara/
2022 Alzheimer’s Disease Public Education Forum and
2022 Care Partner Education Forum Recording
2022 Alzheimer’s Public Education Forum
0:00:00 Ranjan Duara, MD, FAAN
0:02:44 Rosie Curiel Cid, PsyD
0:06:20 Steven DeKosky, MD, FACP, FAAN
0:22:18 Howard Chertkow, MD, FRCP, CAHS
0:45:40 Ranjan Duara, MD, FAAN
1:01:46 Rosie Curiel Cid, PsyD
1:20:50 Marc Agronin, MD
1:36:03 Panel Discussion
1:59:05 Mind&Melody – Eric Guitian
2022 Care Partner Education Forum
2:12:14 Rosie Curiel Cid, PsyD
2:18:30 Finding and Accepting Support
2:50:00 Staying Well while Providing Care
3:14:19 End of Life/Palliative Care
3:34:14 Value of Participating in Research
3:59:17 Sleep Disturbance
We are pleased to welcome again Mind&Melody, a 501(c)(3) organization that uses music to help seniors regain pieces of themselves while instilling purpose and empathy in younger generations. They will perform for our audience during the break of 3:30 pm ET.
Mind&Melody provides over 60+ music enrichment programs in south and north Florida benefiting over 1000 seniors. Since 2014, the organization has been committed to transforming lives through the love of music, implementing an interactive program in healthcare facilities, nursing homes, day centers, and assisted living facilities and at home. Sessions are offered in-person or online.